• /search
  • Servizi
  • Crea un podcast
  • Spreaker
  • Piani e prezzi
  • Ascolta
  • Accedi Registrati
  • Distribuzione
  • Monetizzazione podcast
  • Statistiche per i podcast
  • Podcasting per aziende
  • App di registrazione
  • App per l’ascolto
  • Featured This Week
  • Spreaker's Prime Shows
  • Staff Picks
  • Crime
  • This NFL life 🏈
  • Scopri di più
  • Servizi
    • Distribuzione
    • Monetizzazione podcast
    • Statistiche per i podcast
    • Podcasting per aziende
    • App di registrazione
    • App per l’ascolto
  • Crea un podcast
  • Piani e prezzi
  • Ascolta
    • Featured This Week
    • Spreaker's Prime Shows
    • Staff Picks
    • Crime
    • This NFL life 🏈
    • Scopri di più
  • Registrati SIGN IN
← Esplora

#crizotinib

Tag collegati:

#cancer #lung #cancergrace #grace #gracecast
  • Dr. Greg Riely on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

    Dr. Greg Riely on the Most ...

  • Dr. Geoffrey Oxnard on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

    Dr. Geoffrey Oxnard on the ...

  • Dr. Phil Bonomi on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

    Dr. Phil Bonomi on the Most...

  • Dr. Karen Kelly on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

    Dr. Karen Kelly on the Most...

  • Dr. Bob Doebele on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

    Dr. Bob Doebele on the Most...

  • ALK Positive Lung Cancer Forum 2014: Next Generation ALK Inhibitors

    ALK Positive Lung Cancer Fo...

  • ALK Positive Lung Cancer Forum 2014: Xalkori

    ALK Positive Lung Cancer Fo...

  • ALK Positive Lung Cancer Forum 2014: Disease Progression While on Xalkori

    ALK Positive Lung Cancer Fo...

  • How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?

    How Do the New ALK Inhibito...

  • Here Today Thanks to Research

    Here Today Thanks to Research

  • ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib

    ALK Inhibitors for Acquired...

  • New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1

    New Ideas and New Treatment...

  • Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

    Crizotinib for First Line T...

  • Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC

    Ceritinib and Other Second ...

Altro Sto caricando
Spreaker logo
  • Piani e prezzi
  • Voxnest
  • Blog
  • Lavora con noi
  • Press
  • Scegli una lingua

Per podcaster ed editori

  • Podcasting per aziende
  • Monetizzazione podcast
  • Statistiche per i podcast
  • Distribuzione

Strumenti per i podcaster

  • Come creare un podcast
  • Store di Spreaker
  • App Studio di Spreaker
  • Centro assistenza

Per gli ascoltatori

  • App Podcast di Spreaker

Other Pages

  • Termini
  • Privacy
  • Do Not Sell My Information

Categorie principali

  • Featured This Week
  • Spreaker's Prime Shows
  • Staff Picks
  • Crime
  • This NFL life 🏈
  • Scopri di più

Categorie principali

  • Featured This Week
  • Spreaker's Prime Shows
  • Staff Picks
  • Crime
  • This NFL life 🏈
  • Scopri di più

Seguici su

  • Icona di Facebook Facebook
  • Icona di Twitter Twitter
  • Icona di LinkedIn LinkedIn
  • Icona di Instagram Instagram
Marchio soci IAB

    Other Pages

  • Termini
  • Privacy
  • Do Not Sell My Information

Seguici su

Icona di Facebook Facebook
Icona di Twitter Twitter
Icona di LinkedIn LinkedIn
Icona di Instagram Instagram
iAB member
Copyright 2021 - Spreaker Inc. a Voxnest Company - Crea un podcast - New York, NY
Privacy
Termini
Do Not Sell My Information